Superworth

SELLAS Life Sciences free cash flow SLS

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Dec 31, 2016
−$44.9M
Latest quarter, Q4 FY16
−$8M
Fiscal year 2016
−$44.9M

SELLAS Life Sciences' free cash flow was −$44.9M over the twelve months to Dec 31, 2016.

In its latest quarter, Q4 FY16, it was −$8M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2016−$44.9Mn/a
FY2015−$48.3Mn/a
FY2014−$42.9Mn/a
FY2013n/an/a
FY2011−$14.7Mn/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY16−$8Mn/a−$44.9M
Q3 FY16−$12.2Mn/a−$52.3M
Q2 FY16−$11.5Mn/a−$49.6M
Q1 FY16−$13.2Mn/a−$50M
Q4 FY15−$15.4Mn/a−$48.3M
Q3 FY15−$9.5Mn/a−$43.7M
Q2 FY15−$11.9Mn/a−$45.3M
Q1 FY15−$11.6Mn/a−$46.4M
Q4 FY14−$10.7Mn/a−$42.9M
Q3 FY14−$11.1Mn/a−$40.8M
Q2 FY14−$13Mn/a−$37.8M
Q1 FY14−$8.1Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest SELLAS Life Sciences' size, closest first, today.

CompanyFree cash flow yield
SLSSELLAS Life Sciencesn/m
PBHPrestige Consumer Healthcare10.4%
HRMYHarmony Biosciencesn/m
NRIXNurix Therapeutics13.4%
ANIPANI Pharmaceuticals10.4%
PAHCPhibro Animal Health0.6%
OGNOrganon15.7%
ANABAnaptysbion/m
PCRXPacira BioSciences12.4%
LQDALiquidia3.9%
ARQTArcutis Biotherapeutics1.0%
Peer median10.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on SELLAS Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.